Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Kinstrie R, Horne GA, Morrison H, Irvine D, Munje C, Castañeda EG, Moka HA, Dunn K, Cassels JE, Parry N, Clarke CJ, Scott MT, Clark RE, Holyoake TL, Wheadon H, Copland M. Kinstrie R, et al. Among authors: horne ga. Leukemia. 2020 Jun;34(6):1613-1625. doi: 10.1038/s41375-019-0684-5. Epub 2020 Jan 2. Leukemia. 2020. PMID: 31896780 Free PMC article.
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
Copland M, Slade D, McIlroy G, Horne G, Byrne JL, Rothwell K, Brock K, De Lavallade H, Craddock C, Clark RE, Smith ML, Fletcher R, Bishop R, Milojkovic D, Yap C. Copland M, et al. Lancet Haematol. 2022 Feb;9(2):e121-e132. doi: 10.1016/S2352-3026(21)00370-7. Epub 2021 Dec 11. Lancet Haematol. 2022. PMID: 34906334 Clinical Trial.
Novel drug therapies in myeloid leukemia.
Horne GA, Kinstrie R, Copland M. Horne GA, et al. Pharm Pat Anal. 2015;4(3):187-205. doi: 10.4155/ppa.15.3. Pharm Pat Anal. 2015. PMID: 26030080 Free article. Review.
Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Kinstrie R, Horne GA, Morrison H, Irvine D, Munje C, Castañeda EG, Moka HA, Dunn K, Cassels JE, Parry N, Clarke CJ, Scott MT, Clark RE, Holyoake TL, Wheadon H, Copland M. Kinstrie R, et al. Among authors: horne ga. Leukemia. 2020 Jul;34(7):1975. doi: 10.1038/s41375-020-0721-4. Leukemia. 2020. PMID: 32005922 Free PMC article.
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf TH, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark RE, Milojkovic D, Helgason GV, Foroni L, Nicolini FE, Holyoake TL, Copland M. Horne GA, et al. Leukemia. 2020 Jul;34(7):1775-1786. doi: 10.1038/s41375-019-0700-9. Epub 2020 Jan 10. Leukemia. 2020. PMID: 31925317 Free PMC article. Clinical Trial.
29 results